Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2024-03-10 Epub Date: 2023-10-27 DOI:10.1200/JCO.23.01196

Emmanouil Fokas, J Joshua Smith, Julio Garcia-Aguilar, Robert Glynne-Jones, Marc Buyse, Claus Rödel

引用次数: 0

Abstract

Trial-level surrogacy is critical before early response endpoints are used to approve new therapies.

查看原文本刊更多论文

癌症新辅助直肠试验的早期疗效终点：重新评估代孕。

在使用早期反应终点批准新疗法之前，试验水平的代用性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.